FibroGen

From SourceWatch
(Redirected from Fibrogen)
Jump to navigation Jump to search
This article is a stub. You can help by expanding it.

"FibroGen is a research-based biotechnology company using its expertise in connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology to discover, develop, and commercialize novel therapeutics for serious unmet medical needs." [1]

Board

Accessed December 2010: [2]

  • Thomas B. Neff - Chairman, Founder, Chief Executive Officer
  • Thomas F. Kearns, Jr. - Retired Partner, Bear, Stearns & Co., Inc.
  • Kalevi Kurkijärvi - Senior Partner, Chairman and CEO, BioFund Management Fund Ltd.
  • Miguel Madero - Fomento Direccion, Mexico
  • Rory B. Riggs - Managing Member, Balfour LLC; Former President and Director, Biomatrix, Inc.
  • Roberto Pedro Rosenkranz - Chairman and Chief Executive Officer, ROXRO PHARMA, Inc.; Director, Pherin Pharmaceuticals
  • Jorma Routti - Chairman of the Board of Directors, FibroGen Europe, Former Director General of the Directorate of Science, Research and Development of the European Commission
  • James A. Schoeneck - CEO and Director, BrainCells Inc.
  • Julian N. Stern - Counsel to Goodwin Procter, LLP.
  • Toshinari Tamura - Former Representative Director, Executive Vice President and Chief Science Officer of Astellas Pharma, Inc.

Contact

URL: http://www.fibrogen.com/

Resources and articles

Related Sourcewatch

References

  1. Home, FibroGen, accessed December 10, 2010.
  2. People, FibroGen, accessed December 10, 2010.